CoChat

Cancer therapy using nanoformulated substances: scientific, regulatory and financial aspects

Alphandéry, Edouard, Grand-Dewyse, Pierre, Lefèvre, Raphael, Mandawala, Chalani, Durand-Dubief, Mickael · 2015 · Expert Review of Anticancer Therapy
Cited by 108

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Abstract

Several nanoformulated anti-cancer substances are currently commercialized or under development. Pre-clinical and clinical results have revealed better properties, that is, larger efficacy and lower toxicity for these substances than for conventional anti-cancer treatments. Here, we review the development of several of these substances such as Marqibo, Myocet, Doxil, DaunoXome, MM398, MM302, Mepact, Versamune, Thermodox, Depocyt, Livatag, Abraxane, Eligard, Opaxio, Zinostatin Stimalamer (SMANCS), Pegasys and PegIntron, BIND-014, CRLX-101, Oncaspar, Neulasta, Aurimmune, Auroshell, AuNPs, Nanotherm, NanoXray, Magnetosome chains, Kadcyla (T-DM1), Ontak (DAB/IL2), Gendicine and Curcumin. We describe their specific properties, such as their stability, solubility, mean of administration or targeting, distribution, metabolism and toxicity. We discuss their categorization as medical devices or drugs, their fabrication process within a regulatory environment as well as intellectual property and financial aspects that are all essential to enable their industrial development.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1586/14737140.2015.1086647

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Cited by

See all 108

Metadata

Authors
Alphandéry, E., Grand-Dewyse, P., Lefèvre, R., Mandawala, C., & Durand-Dubief, M.
Venue
Expert Review of Anticancer Therapy
Published
2015-09-24
Volume
15
Issue
10
Pages
1233-1255
ISSN
  • 1473-7140 (ISSN-L)
  • 1744-8328
OpenAlex
W2149144667
Cited by
108
References
6
FWCI
3.26
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Cancer therapy using nanoformulated substances: scientific, regulatory and financial aspects. https://app.cochat.ai/papers/10.1586/14737140.2015.1086647
The paper
Alphandéry, E., Grand-Dewyse, P., Lefèvre, R., Mandawala, C., & Durand-Dubief, M. (2015). Cancer therapy using nanoformulated substances: scientific, regulatory and financial aspects. Expert Review of Anticancer Therapy. https://doi.org/10.1586/14737140.2015.1086647

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.